Welcome to our dedicated page for Puma Biotechnology news (Ticker: PBYI), a resource for investors and traders seeking the latest updates and insights on Puma Biotechnology stock.
Puma Biotechnology Inc (PBYI) is a biopharmaceutical company focused on advancing targeted therapies for cancer treatment, including its commercialized product NERLYNX® (neratinib) for HER2-positive breast cancer. This page provides investors and healthcare professionals with a comprehensive repository of official company announcements and verified news updates.
Access timely information about clinical trial developments, regulatory milestones, and strategic partnerships directly from the source. Our curated collection includes earnings reports, research advancements, and manufacturing updates related to PBYI's oncology portfolio, including updates on alisertib's development as an aurora kinase A inhibitor.
All content is organized chronologically to help track the company's progress in bringing innovative cancer therapies to market through its risk-mitigated in-licensing strategy. Bookmark this page for convenient access to primary source information about PBYI's contributions to precision medicine in oncology care.
Puma Biotechnology (NASDAQ: PBYI) will join the Russell 3000 Index starting July 1, following the annual reconstitution of Russell Investments' equity indexes. This inclusion is based on market-capitalization rankings as of the end of April.
Membership in the Russell 3000 will also mean automatic inclusion in either the Russell 1000 Index or Russell 2000 Index, and relevant growth and value style indexes. It offers increased liquidity and broader exposure to institutional investors, benefiting stockholders.
The Russell indexes, utilized by investment managers and institutional investors, benchmark over $10 trillion in assets. This is a significant development for Puma Biotechnology, aligning them with major U.S. and global equity performance metrics.
Puma Biotechnology announced the release of abstracts on its drug alisertib, which will be presented at the 2024 ASCO Annual Meeting. The event, scheduled from May 31 to June 4 in Chicago and online, will feature two key studies involving alisertib. The first, Abstract 1037, is a phase II study on alisertib in treating endocrine-resistant metastatic breast cancer, with findings presented by Dr. Karthik Giridhar from Mayo Clinic. The second, Abstract 8572, explores a phase I/Ib study of alisertib combined with osimertinib for osimertinib-resistant EGFR-mutated lung cancer, presented by Dr. Turja Chakrabarti from the University of California, San Francisco. Full abstracts are available online.
Puma Biotechnology, Inc. (NASDAQ: PBYI) reported its first quarter financial results for 2024, with $40.3 million in product revenue, a net loss of $4.8 million, and $107.2 million in cash reserves. Key milestones include clinical trials for lung and breast cancer treatments. Total revenue was $43.8 million, with operating costs of $46.1 million. Second quarter and full-year 2024 financial outlook projects net product revenue of $43-45 million and $183-190 million, respectively.
FAQ
What is the current stock price of Puma Biotechnology (PBYI)?
What is the market cap of Puma Biotechnology (PBYI)?
